North American Regulatory Milestone

Biotalys Advances towards Registration of EVOCA in California with Start of Public Consultation

CDPR Initiates 30-Day Public Phase Following Favorable Human Health Assessment for Protein-Based Biofungicide

In a major step toward expanding biological options within the nation’s premier specialty crop corridors, Biotalys Advances towards Registration of EVOCA in California with Start of Public Consultation. Announced on July 1, 2026, the California Department of Pesticide Regulation (CDPR) has officially opened its 30-day public comment phase for the EVOCA® dossier, running through July 26. This milestone follows a positive scientific review by the CDPR’s Human Health Assessment Branch, which concluded that the toxicology data packages fully support state registration. Following its recent approval in Florida, clearing California’s rigorous safety benchmarks establishes the state baseline to unlock the global registration pipeline for the company’s next-generation AGROBODY® platform, positioning the commercial biofungicide EVOCA NG for a targeted U.S. launch in 2029.

________

GHENT, BELGIUM — July 01, 2026 — Biotalys (Euronext Brussels: BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, today announces further progress in the regulatory review process of its first biofungicide, EVOCA®, in the United States.

The California Department of Pesticide Regulation (CDPR), Pesticide Registration Branch, has now initiated the public consultation phase of the EVOCA dossier, marking an important step forward in the evaluation process. This milestone follows the recommendation by CDPR’s Human Health Assessment Branch, which concluded that the data and information submitted by Biotalys support the registration of EVOCA in California.

California represents the largest agricultural state in the U.S., including the production of high-value fruits and vegetables such as strawberries, tomatoes, and grapes, making it a highly strategic market for Biotalys’ biocontrol pipeline. Earlier this year, the company received regulatory approval for EVOCA in Florida – its first U.S. state approval for a biofungicide developed by the firm.

“The start of the public consultation by the CDPR marks an important and encouraging milestone in the regulatory review of EVOCA in California, as the CDPR is known to perform an extensive review of scientific data, including efficacy and field validation, under some of the most stringent safety and environmental standards globally,” said Carlo Boutton, Chief Executive Officer of Biotalys.

The public consultation phase consists of a 30-day comment period, during which stakeholders and the public can provide feedback on the proposed decision. Upon closure of the consultation scheduled for 26 July, CDPR is expected to review the submitted comments and progress toward a final state regulatory decision in the second half of 2026.

“The positive assessment by the Human Health Assessment Branch reinforces our confidence in the strength of our data package and in the potential of our AGROBODY® technology platform to deliver a new generation of effective, protein-based crop protection solutions. California is one of the world’s most important agricultural markets, and progress in this process brings us one step closer to offering growers innovative tools that can help make food production more sustainable,” added Boutton.

About EVOCA® and the Platform Pipeline

EVOCA® is an innovative, protein-based AGROBODY® biocontrol formulated to safely suppress the destructive fungal diseases Botrytis (grey mold) and powdery mildew across high-value fruit and vegetable crops. By providing an innovative mode of action, the biofungicide enables fruit and vegetable growers to rotate chemical inputs and combat spreading pathogen resistance without generating chemical residues or harvest-interval penalties.

Crucially, the regulatory validation and state registration of EVOCA paves the way for the impending submission of EVOCA NG, the product’s next-generation version containing the same active protein ingredient but optimized for industrial scale-up. EVOCA NG is engineered to serve as Biotalys’ first full-scale commercial biofungicide asset, with a planned market rollout in the United States in 2029 and a European Union expansion scheduled for 2030, targeting an addressable combined market evaluated at roughly USD 1.1 billion.

About Biotalys

Biotalys is an innovative Agricultural Technology company developing precision protein-based biocontrol solutions to protect global crops across both pre- and post-harvest value chains. Founded in 2013 as a specialized spin-off from the VIB (Flanders Institute for Biotechnology) and listed on Euronext Brussels, the firm bridges the targeted efficacy metrics of traditional crop chemistry with the favorable safety profiles of biological tools. The company operates from its headquarters within the premier biotechnology cluster in Ghent, Belgium.

Biotalys N.V. — Corporate Press & Regulatory Registry

Ghent, Belgium & Sacramento, CA | CDPR State Filing Dossier Briefing | July 2026 | biotalys.com